Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
Bioventus Inc.NASDAQ: BVS
Operating Margin · Q1 FY2026 · quarter ended Mar 2026
Operating margin widens to 6.7%
Operating margin was 6.7% in Q1 FY2026, up 2.7 pp from a year earlier. On a trailing-twelve-month basis it was 10.6%, up 13.2 pp year over year. Over 3 fiscal years it widened by 43.0 pp.
Context
- Operating margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether operating margin reaches the consensus estimate from 4 analysts of 16.1% for the fiscal year ending Dec 2026, up from 10.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 6.7%-7.0 pp QoQ
- Last fiscal yearDec 2025
- 10.3%+12.4 pp YoY
- LTMMar 2026
- 10.6%+13.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.7 pp | +1.5 pp | -1.3 pp |
| 1 year | +12.4 pp | +5.8 pp | -6.6 pp |
| 3 years | +43.0 pp | +9.9 pp | -33.1 pp |
| 5 years | +7.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 10.3%
- Year-over-year change
- +12.4pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.3% | +12.4pp |
| FY2024 | 2024-12-31 | -2.1% | +13.9pp |
| FY2023 | 2023-12-31 | -16.0% | +16.7pp |
| FY2022 | 2022-12-31 | -32.7% | -35.5pp |
| FY2021 | 2021-12-31 | 2.8% | — |
Operating Margin vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 operating margin of 10.6% is the 2nd highest of the 9 companies compared; the peer median is 2.4%.
- Its year-over-year change of +13.2 pp is the highest of 9, against a peer median of +6.5 pp.
- Over three fiscal years its change of +43.0 pp compares with a peer median of +4.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| FY2025 | 12.9% | +1.6 pp | +4.3 pp | |
| LTM Mar 2026 | 10.6% | +13.2 pp | +43.0 pp | |
| LTM Mar 2026 | 10.2% | -5.1 pp | +20.8 pp | |
| LTM Mar 2026 | 7.5% | +7.0 pp | -11.2 pp | |
| LTM Mar 2026 | 2.7% | +8.9 pp | +17.1 pp | |
| LTM Mar 2026 | 2.1% | +6.0 pp | +5.0 pp | |
| LTM Mar 2026 | -4.0% | +8.9 pp | -5.4 pp | |
| LTM Mar 2026 | -10.5% | -3.9 pp | -13.0 pp | |
| LTM Jun 2026 | -42.6% | +6.9 pp | +52.1 pp | |
| Peer median (excluding BVS) | 2.4% | +6.5 pp | +4.6 pp | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 430.9M | 512.12M | 512.35M | 573.28M | 568.09M |
| Cost of Revenue | 128.19M | 181.04M | 184.15M | 185.05M | 185.66M |
| Gross Profit | 302.71M | 331.08M | 328.19M | 388.23M | 382.43M |
| Gross Margin | 70.3% | 64.6% | 64.1% | 67.7% | 67.3% |
| Research & Development | 19.04M | 23.85M | 13.45M | 13.64M | 12.11M |
| Selling, General & Admin | 254.25M | 332.13M | 303.88M | 327.09M | 311.77M |
| Operating Expenses | 290.65M | 498.31M | 409.92M | 400.21M | 323.88M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| EBITDA | 45.48M | (121.61M) | (23.07M) | 39.22M | 99.21M |
| EBITDA Margin | 10.6% | -23.7% | -4.5% | 6.8% | 17.5% |
| Operating Income | 12.06M | (167.23M) | (81.73M) | (11.98M) | 58.55M |
| Operating Margin | 2.8% | -32.7% | -16.0% | -2.1% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.11M | 12.02M | 40.68M | 38.79M | 26.49M |
| Other Income / Expenses | (2.57M) | (21.79M) | (39.39M) | (37.15M) | (32.84M) |
| Income Before Tax | 9.49M | (189.03M) | (121.11M) | (49.13M) | 25.71M |
| Pre-Tax Margin | 2.2% | -36.9% | -23.6% | -8.6% | 4.5% |
| Income Tax Expense | (1.97M) | (44.37M) | 85K | (5.29M) | (1.57M) |
| Net Income | 19.38M | (158.7M) | (156.23M) | (33.54M) | 22.73M |
| Net Margin | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% |
| EPS (Basic) | (0.15) | (2.59) | (2.49) | (0.52) | 0.34 |
| EPS (Diluted) | (0.15) | (2.59) | (2.49) | (0.52) | 0.33 |
| Weighted Avg Shares | 45.47M | 61.39M | 62.65M | 65.36M | 66.62M |
| Weighted Avg Shares (Diluted) | 45.47M | 61.39M | 62.65M | 65.36M | 68.91M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.